Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).

Reungwetwattana T, Weroha SJ, Molina JR.

Clin Lung Cancer. 2012 Jul;13(4):252-66. doi: 10.1016/j.cllc.2011.09.004. Epub 2011 Dec 8. Review.

PMID:
22154278
2.

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M; University of Hong Kong Lung Cancer Study Group.

Cancer. 2009 Apr 15;115(8):1723-33. doi: 10.1002/cncr.24181.

3.

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.

Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C, McDougall J, Wylie AA, Robison K, Caliri K, Palombella VJ, Fritz CC.

Oncogene. 2011 Jun 2;30(22):2581-6. doi: 10.1038/onc.2010.625. Epub 2011 Jan 24.

PMID:
21258415
4.

ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.

Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC.

Eur J Cancer. 2012 May;48(7):961-73. doi: 10.1016/j.ejca.2012.02.001. Epub 2012 Mar 6.

PMID:
22397764
5.

Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.

Okamoto I, Nakagawa K.

Cancer Sci. 2012 Aug;103(8):1391-6. doi: 10.1111/j.1349-7006.2012.02327.x. Epub 2012 Jun 17. Review.

6.

Molecular oncology of lung cancer.

Toyooka S, Mitsudomi T, Soh J, Aokage K, Yamane M, Oto T, Kiura K, Miyoshi S.

Gen Thorac Cardiovasc Surg. 2011 Aug;59(8):527-37. doi: 10.1007/s11748-010-0743-3. Epub 2011 Aug 18. Review.

PMID:
21850578
7.

[Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation].

Zeng Z, Wu Y.

Zhongguo Fei Ai Za Zhi. 2011 Nov;14(11):880-4. doi: 10.3779/j.issn.1009-3419.2011.11.09. Review. Chinese.

8.

Targeted therapies for non-small cell lung cancer.

Dempke WC, Suto T, Reck M.

Lung Cancer. 2010 Mar;67(3):257-74. doi: 10.1016/j.lungcan.2009.10.012. Epub 2009 Nov 14. Review.

PMID:
19914732
9.

Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer.

Mino-Kenudson M, Mark EJ.

Arch Pathol Lab Med. 2011 May;135(5):655-64. doi: 10.1043/2011-0029-RAI.1. Review.

PMID:
21526964
10.

[Diagnostic and therapeutic biomarkers for lung cancer patients].

Seike M, Gemma A.

Nihon Rinsho. 2012 May;70(5):809-15. Review. Japanese.

PMID:
22620005
11.

[A new target in non-small cell lung cancer: EML4-ALK fusion gene].

Wang H, Yuan J, Ma Z.

Zhongguo Fei Ai Za Zhi. 2011 Jun;14(6):538-42. doi: 10.3779/j.issn.1009-3419.2011.06.11. Review. Chinese.

12.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H.

Nature. 2007 Aug 2;448(7153):561-6. Epub 2007 Jul 11.

PMID:
17625570
13.

New molecular targets in the treatment of NSCLC.

Schettino C, Bareschino MA, Sacco PC, Maione P, Rossi A, Casaluce F, Sgambato A, Gridelli C.

Curr Pharm Des. 2013;19(30):5333-43. Review.

PMID:
23394083
14.

First-line therapy of mutated non-small cell lung cancer: an update.

Stöhlmacher-Williams J.

Onkologie. 2012;35(5):293-9. doi: 10.1159/000338529. Epub 2012 Apr 24. Review.

PMID:
22868512
15.

Targeted therapies for advanced non-small-cell lung cancer: current status and future implications.

Custodio A, Méndez M, Provencio M.

Cancer Treat Rev. 2012 Feb;38(1):36-53. doi: 10.1016/j.ctrv.2011.04.001. Epub 2011 May 17. Review.

PMID:
21592673
16.

Novel therapeutic targets in non-small cell lung cancer.

Alamgeer M, Ganju V, Watkins DN.

Curr Opin Pharmacol. 2013 Jun;13(3):394-401. doi: 10.1016/j.coph.2013.03.010. Epub 2013 Apr 20. Review.

PMID:
23608109
17.

New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.

Crawford J.

J Natl Compr Canc Netw. 2003 Jan;1 Suppl 1:S78-86. Review.

PMID:
19795580
18.

Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

Janku F, Stewart DJ, Kurzrock R.

Nat Rev Clin Oncol. 2010 Jul;7(7):401-14. doi: 10.1038/nrclinonc.2010.64. Epub 2010 Jun 15. Review. Erratum in: Nat Rev Clin Oncol. 2011 Jul;8(7):384.

PMID:
20551945
19.
20.

A decade of advances in treatment for advanced non-small cell lung cancer.

Gettinger S, Lynch T.

Clin Chest Med. 2011 Dec;32(4):839-51. doi: 10.1016/j.ccm.2011.08.017. Review.

PMID:
22054890

Supplemental Content

Support Center